1. UpToDate web sitesi. https://www.uptodate.com/contents/society-guideline-links-covid-19-general-guidelines-for-management (Erişim tarihi: 1 Şubat 2024)
2. Sağlık Bakanlığı web sitesi. https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html (Erişim tarihi: 1 Şubat 2024)
3. Therapeutics and COVID-19: living guideline, 10 November 2023. Geneva: World Health Organization; 2023 (WHO/2019-nCoV/therapeutics/2023.2). Licence: CC BY-NC-SA 3.0 IGO.
4. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodríguez-Baño J. European
society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. Clin Microbiol Infect. 2022
Dec;28(12):1578-1590.
5. British Medical Journal web sitesi. https://www.bmj.com/content/370/bmj.m2980 (Erişim tarihi: 5 Şubat 2024)
6. UpToDate web sitesi. https://www.uptodate.com/contents/covid-19-management-in-hospitalized-adults (Erişim tarihi: 5 Şubat 2024)
7. Looi M. What are the latest covid drugs and treatments? BMJ 2023; 381 :p872 doi:10.1136/bmj.p872
8. IDSA (Amerika Enfeksiyon Hastalıkları Derneği) web sitesi. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#OverviewofCOVID-19Treat-
mentGuidelinesSummaryTable (Erişim tarihi: 5 Şubat 2024)
9. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ (Erişim tarihi: 9 Şubat 2024)
10. Fischer WA II, Eron JJ Jr, Holman W, et al. A Phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious
virus. Sci Transl Med. 2022;14(628):eabl7430.
11. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-520.
12. Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled tri-
al. Ann Intern Med. 2022;175(8):1126-1134.
13. Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANO-
RAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281-293.
14. FDA web sitesi. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio (molnupiravir) capsules. 2023. https://www.fda.gov/me-
dia/155054/download (Erişim tarihi: 9 Şubat 2024)
15. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with
high potency. J Biol Chem. 2020;295(20):6785–97.
16. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.
17. FDA web sitesi. Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf. (Erişim tarihi:
12 Şubat 2024)
18. Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. Co-
chrane Database Syst Rev. 2023 Jan 25;1(1):CD014962.
19. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386(4):305-315.
20. Blair HA. Remdesivir: A Review in COVID-19. Drugs. 2023 Sep;83(13):1215-1237. doi: 10.1007/s40265-023-01926-0. Epub 2023 Aug 17. Erratum in: Drugs. 2023 Sep;83(14):1349.
21. Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and
small molecule chemotherapy. J Med Chem. 2016;59(14):6595-6628.
22. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 MPRO inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.
23. FDA web sitesi. Ritonavir-boosted nirmatrelvir (Paxlovid) [package insert]. Food and Drug Administration. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s-
000lbl.pdf. (Erişim tarihi: 15 Şubat 2024)
24. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408.
25. Hammond J, Fountaine RJ, Yunis C et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med. 2024 Apr 4;390(13):1186-1195.
26. Gandhi RT, Hirsch M. Treating Acute Covid-19 — Final Chapters Still Unwritten, New England Journal of Medicine, 390, 13, (1234-1236), (2024).
27. Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77-84.
28. Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe COVID-19 outcomes during the Omicron surge. N Engl J Med. 2022;387(9):790-798.
29. Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563-572.
30. Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022. MMWR Morb Mortal Wkly
Rep. 2022;71(48):1531-1537.
31. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir–paxlovid-/
(Erişim tarihi: 15 Şubat 2024)
32. Li, G., Hilgenfeld, R., Whitley, R. et al. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov 2023; 22: 449–75.
33. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/anti-sars-cov-2-monoclonal-antibodies/ (Eri-
şim tarihi: 15 Şubat 2024)
34. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/ (Erişim tarihi:
15 Şubat 2024)
35. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/summary-recommendations/ (Erişim tarihi: 5 Mart 2024)
36. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med . 2021;384(8):693-704.
37. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/systemic-corticosteroids/ (Erişim tarihi: 5 Mart 2024)
38. REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384(16):1491-1502.
39. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet.
2021;397(10285):1637-1645.
40. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized
controlled Phase 3 trial. Nat Med. 2021;27(10):1752-1760.
41. CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised
controlled trial. Lancet Respir Med. 2021;9(3):295-304.
42. Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, et al. Efficacy and safety of anakinra plus standard of care for patients with severe COVID-19: a randomized Phase 2/3 clinical trial. JAMA
Netw Open. 2023;6(4):e237243.
43. Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised,
controlled trial. Lancet Respir Med. 2021;9(12):1427-1438.
44. Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022;1(1):CD015308.
45. Dahms K, Mikolajewska A, Ansems K, et al. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):100.
46. Wise J. Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows. BMJ 2021; 372: n433.
47. Sun J, Wang S, Ma X, Wei Q, Peng Y, Bai Y, Miao G, Meng C, Liu P. Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-a-
nalysis. Eur J Med Res. 2023 Nov 21;28(1):536.
48. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/janus-kinase-inhibitors/ (Erişim tarihi: 15 Mart 2024)
49. Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406-415.
50. NIH (Ulusal Sağlık Enstitüsü) web sitesi. https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/ (Erişim tarihi: 15 Mart 2024)
51. Connors JM, Brooks MM, Sciurba FC, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized
clinical trial. JAMA. 2021;326(17):1703-1712.
52. Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label,
multicentre, randomised, controlled, Phase 3b trial. Lancet Haematol. 2022;9(8):e594-e604.
53. Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, Phase
3 trial. Lancet Haematol. 2022;9(8):e585-e593.